GlassScriptPhysician profile
Ilaria Reyes
NPI 1912354242
$4,711.85
in general payments reported to CMS, 2019-2025
34 companies · $1,319 in 2025
The $1,319 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $935 · 2022: $1,037 · 2023: $687 · 2024: $734 · 2025: $1,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,740.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $748.52 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $719.85 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Nevro Corp. | $511.84 | 2021-2024 | Senza |
| Dexcom, INC. | $266.38 | 2021-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Amgen INC. | $239.27 | 2022-2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $172.07 | 2024-2025 | |
| Glaxosmithkline, LLC. | $150.28 | 2022 | |
| Integra Lifesciences Corporation | $127.72 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2021 | |
| Idorsia Pharmaceuticals US INC | $124.04 | 2023 | Quviviq |
| Genzyme Corporation | $121.90 | 2024 | |
| Abbvie INC. | $119.14 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $117.17 | 2025 | Voquezna |
| Corcept Therapeutics | $114.27 | 2022 | |
| Sanofi-Aventis U.S. LLC | $110.55 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $107.34 | 2025 | Freestyle Libre 3 |
| Organogenesis INC. | $85.14 | 2022 | |
| Esperion Therapeutics, INC. | $83.87 | 2021 | |
| Medtronic, INC. | $81.05 | 2025 | Turbohawk |
| Inspire Medical Systems, INC. | $80.49 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.87 | 2023-2025 | Jardiance, Tradjenta |
| E.R. Squibb & Sons, L.L.C. | $74.17 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $70.70 | 2024 | Iqirvo |
| Shield Therapeutics INC | $33.71 | 2025 | |
| Alk-Abello, INC | $32.79 | 2024 | Odactra, Grastek, Ragwitek |
| Pfizer INC. | $32.43 | 2025 | |
| Exact Sciences Corporation | $31.77 | 2025 | Cologuard Collection Kit |
| Organon LLC | $31.10 | 2023 | Nexplanon |
| Intuitive Surgical, INC. | $27.62 | 2021 | |
| Horizon Therapeutics Plc | $25.71 | 2021 | |
| Melinta Therapeutics, LLC | $20.10 | 2023 | Kimyrsa |
| Currax Pharmaceuticals LLC | $17.73 | 2024 | Contrave |
| Astrazeneca Pharmaceuticals LP | $16.43 | 2023 | Farxiga |
| Bioventus LLC | $12.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilaria Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.